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In Brief
The ATPase activity of Hsp90 is essential
for its chaperoning function and can be
stimulated by the co-chaperone, Aha1.
Tyrosine phosphorylation of Aha1 by the
c-Abl kinase promotes its interaction with
Hsp90 and enhances its chaperone
activity toward kinases.
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The ability of Heat Shock Protein 90 (Hsp90) to
hydrolyze ATP is essential for its chaperone function.
The co-chaperone Aha1 stimulates Hsp90 ATPase
activity, tailoring the chaperone function to specific
‘‘client’’ proteins. The intracellular signaling mecha-
nisms directly regulating Aha1 association with
Hsp90 remain unknown. Here, we show that c-Abl ki-
nase phosphorylates Y223 in human Aha1 (hAha1),
promoting its interaction with Hsp90. This, conse-
quently, results in an increased Hsp90 ATPase activ-
ity, enhances Hsp90 interaction with kinase clients,
and compromises the chaperoning of non-kinase cli-
ents such as glucocorticoid receptor andCFTR. Sug-
gesting a regulatory paradigm, we also find that Y223
phosphorylation leads to ubiquitination and degra-
dation of hAha1 in the proteasome. Finally, pharma-
cologic inhibition of c-Abl prevents hAha1 interaction
with Hsp90, thereby hypersensitizing cancer cells to
Hsp90 inhibitors both in vitro and ex vivo.INTRODUCTION
The essential eukaryotic molecular chaperone Heat Shock Pro-
tein 90 (Hsp90) is involved in folding and stability of target pro-1006 Cell Reports 12, 1006–1018, August 11, 2015 ª2015 The Authoteins, also referred to as ‘‘clients’’ (Ro¨hl et al., 2013; Taipale
et al., 2010). Hsp90 has approximately 200 clients (listed at
http://www.picard.ch/downloads/Hsp90interactors.pdf). They
are broadly classified as kinase clients, such as ErbB2, c-Met,
and CDK4 and non-kinase clients including heat shock factor,
steroid hormone receptors, and cystic fibrosis transmembrane
conductance regulator (CFTR). The majority of the kinase clients
are involved in oncogenesis, therefore Hsp90 is recognized as a
facilitator of ‘‘oncogene addiction’’ (Neckers and Workman,
2012).
The Hsp90 structure consists of homodimer molecules with
N-, middle, and C-domains. ATP binding to the N-domain and
its subsequent hydrolysis are linked to Hsp90 chaperone func-
tion (Obermann et al., 1998; Panaretou et al., 1998). Nucleotide
binding and Hsp90 ATPase activity confer different conforma-
tional states that allow clients to bind and dissociate from
Hsp90 (Hessling et al., 2009; Mickler et al., 2009). The chaperone
activity of Hsp90 is tightly regulated by co-chaperones and post-
translational modifications (PTMs) (Cox and Johnson, 2011;Wal-
ton-Diaz et al., 2013). Co-chaperones are groups of proteins that
interact with distinct conformations of Hsp90, regulating chap-
erone function by either accelerating or decelerating the
ATPase activity or simply acting as scaffolds between Hsp90
and its clients. Our work and studies by other groups have shown
that PTMs of Hsp90 can impact its interaction with co-chaper-
ones. The evolutionarily conserved co-chaperone Aha1 is the
activator of the Hsp90 ATPase activity (Panaretou et al., 1998).
It is also the most common co-chaperone whose interaction isrs
affected by phosphorylation, acetylation, and SUMOylation of
Hsp90 (Mollapour et al., 2011, 2014; Xu et al., 2012).
Amajor gap in our knowledge is how intracellular signals to the
co-chaperone Aha1 dictate its interaction with Hsp90. Our study
demonstrates that c-Abl tyrosine kinase phosphorylates a single
tyrosine residue, Y223, in human Aha1 (hAha1). This, in turn, ap-
pears to promote its association with human Hsp90a (hHsp90a)
and modify chaperoning of kinase clients, heat shock factor,
glucocorticoid receptor (GR), and CFTR. Tyrosine phosphoryla-
tion of hAha1 is also a pre-requisite for its ubiquitination and
degradation in the proteasome.
Hsp90 chaperone function can be inhibited by small mole-
cules that bind to the N-domain ATP-binding pocket, precluding
ATP binding and hydrolysis. There are 16 different Hsp90 inhib-
itors that are currently undergoing clinical evaluation in cancer
patients (Neckers and Workman, 2012). Co-chaperones and
PTMs can affect the efficacy of Hsp90 inhibitors (Walton-Diaz
et al., 2013). Here, we report that the pharmacologic inhibition
of c-Abl prevents hAha1 interaction with hHsp90a and hypersen-
sitizes renal cell carcinoma (RCC) to Hsp90 inhibitors in vitro and
ex vivo.
RESULTS
c-Abl Phosphorylates Y223 in the Co-chaperone Aha1
Hsp90 and the majority of its co-chaperones are phospho-pro-
teins (Walton-Diaz et al., 2013). To determine whether Aha1 is
subject to tyrosine phosphorylation, hAha1-FLAG was tran-
siently expressed in HEK293 cells and by using a pan-anti-phos-
pho-tyrosine antibody (4G10), we readily detected the tyrosine
phosphorylation of hAha1 (Figure 1A). hAha1 has seven tyrosine
residues (Figure 1B), which were individually mutated to non-
phosphorylatable phenylalanine and transiently expressed in
HEK293 cells. Individual mutation of Y81, Y99, Y223, and Y333
to phenylalanine significantly reduced the tyrosine phosphoryla-
tion of hAha1 (Figure S1A). We identified Y223 within the c-Abl
recognition motif I/V/L-YXXP/F (Ubersax and Ferrell, 2007) (Fig-
ure 1B). Therefore, we bacterially expressed and purified
N-terminally His6-tagged hAha1, as well as the seven individual
non-phosphorylatable hAha1 mutants. These purified proteins
were bound to Ni-NTA agarose and used as substrates in an
in vitro kinase assay, which included pure and active c-Abl-glu-
tatione S-transferase (GST). Under these conditions, c-Abl-GST
efficiently phosphorylated hAha1 and individual non-phosphory-
latable tyrosine mutants except for the Y223F (Figure 1C). These
results provide strong evidence that c-Abl directly phosphory-
lates Y223-hAha1, and this is the only tyrosine residue in
hAha1 that is targeted by c-Abl (Figure 1C).
Further evidence for this process, in vivo, was obtained by
transiently co-transfecting HEK293 cells with c-Abl plasmid
and either with FLAG-tagged hAha1 or non-phosphorylatable
Y223F mutant. Overexpression of c-Abl increased the tyrosine
phosphorylation of hAha1. However, this increase in tyrosine
phosphorylation is abolished with hAha1-Y223F mutant (Fig-
ure 1D). We also performed similar experiments with 5-(1,3-dia-
ryl-1H-pyrazol-4-yl)hydantoin, 5-[3-(4-fluorophenyl)-1-phenyl-
1H-pyrazol-4-yl]-2,4-imidazolidinedione (DPH), which binds to
the myristoyl binding site of c-Abl and leads to activation of itsCellkinase activity (Yang et al., 2011). HEK293 cells transiently ex-
pressing wild-type hAha1-FLAG or Y223F mutant were treated
with 20 mMDPH showed an increase in tyrosine phosphorylation
of hAha1, but not of the Y223F mutant (Figure 1E).
We further confirmed this data by transiently expressing
FLAG-hAha1 and Y223F mutant in a c-Abl deficient (c-Abl/)
murine embryo fibroblasts (MEF) cell line and the wild-type
MEF cell line (c-Abl+/+) (Figure 1F). Tyrosine phosphorylation
of hAha1 was significantly reduced in c-Abl deficient MEF
cells (Figure 1F). This reduction was at the same level of Y223F
mutant expressed either in the c-Abl+/+ or c-Abl/ MEF cells
(Figure 1F).
With the exception of the Wee1 tyrosine kinase, the yeast
Saccharomyces cerevisiae does not have a bona fide tyrosine ki-
nase offering a null background for the expression of mammalian
tyrosine kinase c-Abl. We expressed FLAG-tagged hAha1 and
the Y223F mutant in wild-type yeast strain W303; expression
of these alleles was under the control of the native promoter of
yeast AHA1 (yAHA1). We also co-expressed full-length c-Abl,
controlled by the galactose inducible promoter of GAL1. Tyro-
sine phosphorylation of hAha1 was not observed in wild-type
yeast (Figure 1G). However, after inducing c-ABL1 expression
by growing the cells on galactose media, we detected tyrosine
phosphorylation of wild-type hAha1. The non-phosphorylatable
Y223Fmutant remained unmodified (Figure 1G). Taken together,
our data provide strong evidence that c-Abl targets and phos-
phorylates hAha1-Y223.
Subsequently, we investigatedwhether phosphorylation of the
hAha1-Y223 occurred before or after binding to hHsp90. The
presence of endogenous hHsp90 and lack of efficient knock-
down of hHsp90 precluded addressing this issue in mammalian
cell lines. Therefore, we utilized our in vitro kinase assay to
explore the dynamics of hAha1-Y223 phosphorylation. Bacteri-
ally expressed and purified FLAG-hAha1 was immobilized on
anti-FLAG M2 affinity gel. As shown earlier, (Figure 1C), purified
and active c-Abl-GST phosphorylates hAha1 (Figure 1H). This
was detected using a pan-anti-phosphotyrosine antibody.
Immunoprecipitation of FLAG-hAha1 did not co-immunoprecip-
itate c-Abl-GST, suggesting that the interaction between hAha1
and c-Abl is transient (Figure 1H). We carried out a similar in vitro
kinase assay, modified with the addition of hHsp90a, initially, fol-
lowed by c-Abl. This promoted a hAha1-c-Abl-hHsp90a com-
plex formation, but did not increase the tyrosine phosphorylation
of hAha1 (Figure 1H). Addition of calf-intestinal alkaline phospha-
tase (CIAP) caused dephosphorylation of hAha1 and de-stabi-
lized the hAha1-c-Abl-Hsp90a complex (Figure 1H, last lane).
Also, c-Abl does not phosphorylate hHsp90a (Figure S1B).
Taken together, our data suggest that c-Abl has the ability to
phosphorylate hAha1-Y223 even in the absence of hHsp90a.
This fosters formation of a hAha1-c-Abl-hHsp90a complex.
Y223 Phosphorylation Leads to hAha1 Ubiquitination
and Degradation in Proteasomes
Our data suggest a model where tyrosine phosphorylation of
hAha1 promotes interaction, while a possible dephosphorylation
disrupts interaction with hHsp90. However, we sought to
examine whether phosphorylation of hAha1 serves any addi-
tional functions. First, we characterized the intracellularReports 12, 1006–1018, August 11, 2015 ª2015 The Authors 1007
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Figure 1. c-Abl Mediated Tyrosine Phos-
phorylation of hAha1
(A) HEK293 cells were transiently transfected with
empty plasmid (C) or hAha1-FLAG construct. The
hAha1-FLAG was immunoprecipitated (IP) and
tyrosine phosphorylation was detected by immu-
noblotting with pan anti-phospho-tyrosine anti-
body (4G10).
(B) Schematic representation of hAha1 showing all
tyrosine residues and also the putative c-Abl tar-
geted tyrosine consensus motif. The amino acid
residues 162–201 correspond to linker (L) region.
(C) hAha1 tyrosine residues were mutated indi-
vidually to phenylalanine (F), expressed, and pu-
rified from bacteria. The active c-Abl-GST was
used to phosphorylate hAha1 wild-type (WT) and
its non-phosphorylatable mutants in vitro. The
tyrosine phosphorylation was detected by immu-
noblotting with pan anti-phospho-tyrosine anti-
body (4G10).
(D) HEK293 cells were transiently transfected with
c-Abl and hAha1-FLAG (WT) or the non-phos-
phorylatable Y223F mutant. The tyrosine phos-
phorylation of IP hAha1-FLAG was detected by
immunoblotting with pan anti-phospho-tyrosine
antibody (4G10).
(E) hAha1-FLAG (WT) or the non-phosphorylatable
Y223F mutant constructs were used to transiently
transfect HEK293 cells for 24 hr. The cells were
then treated with 20 mM DPH for 6 hr prior to lysis.
The tyrosine phosphorylation of IP hAha1-FLAG
was detected by immunoblotting with pan anti-
phospho-tyrosine antibody (4G10).
(F) c-Abl deficient (c-Abl/) MEF cell line and the
WT MEF cell line (c-Abl+/+) were transiently
transfected with hAha1-FLAG (WT) or the non-
phosphorylatable Y223F mutant. The IP hAha1-
FLAG was immunoblotted and tyrosine
phosphorylation was detected with pan anti-
phospho-tyrosine antibody (4G10).
(G) WT yeast cells co-expressing GAL1-cABL1
and hAHA1-FLAG or Y223F mutant under yAHA1
native promoter were grown on either raffinose ()
or galactose (+). The tyrosine phosphorylation of
hAha1 was assessed by IP and immunoblotting.
(H) In vitro phosphorylation of hAha1-Y223 by a purified and active c-Abl. The hAha1-FLAG or hAha1-Y223F-FLAG were bound to FLAG-beads and phos-
phorylated by active c-Abl-GST. The reaction was also carried out with the addition of hHsp90a-His6. The dephosphorylation of hAha1-Y223 was performed by
addition of CIAP.distribution of hAha1 as the result of phosphorylation of Y223.
HEK293 cells were transiently co-transfected with hHsp90a-HA,
wild-type hAha1-FLAG, and non-phosphorylatable Y223F or
phosphomimetic Y223E mutants. We performed immunofluo-
rescence microscopy, staining the cells with anti-FLAG antibody
and co-staining with anti-HA antibody and DAPI. There were
82% of cells expressing the hAha1-Y223F mutant that showed
nuclear-cytoplasmic localization and 18% with cytoplasmic
localization, whereas 100% of cells expressing the Y223E
mutant displayed cytoplasmic localization (Figures 2A, 2B, and
S2; Table S1).
Protein phosphorylation often serves as a signal prompting
ubiquitination and subsequent proteasome-mediated degrada-
tion of the substrate. Supporting this possibility, HEK293 cells
transiently expressing the wild-type hAha1-FLAG or non-phos-1008 Cell Reports 12, 1006–1018, August 11, 2015 ª2015 The Authophorylatable hAha1-Y223F-FLAG mutant were treated with
5 mM proteasome inhibitor, MG132, for 6 hr (Figure 2C).
hAha1-FLAG proteins were immunoprecipitated with anti-
FLAGM2 affinity gel and then salt-stripped with 0.5 M NaCl prior
to analysis by immunoblotting (Figure 2C). Ubiquitination of
hAha1 was significantly decreased in hAha1-Y223F samples
treated withMG132 (Figure 2C). This finding suggests that phos-
phorylation of Y223 is a prerequisite for ubiquitination and degra-
dation of hAha1 in the proteasome. It is noteworthy that salt-
stripping of our samples prevented the interaction of proteins
with hAha1, and the efficacy of the salt-stripping procedure
was confirmed by checking for the co-precipitation of hHsp90
(data not shown). Therefore, only ubiquitinated hAha1 is visual-
ized in Figure 2B, as opposed to ubiquitinated proteins in com-
plex with hAha1.rs
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Figure 2. Y223 Phosphorylation Leads to
Ubiquitination and Degradation of hAha1 in
Proteasomes
(A) HEK293 cells were co-transfected with
hHsp90a-HA and either empty plasmid pcDNA3,
hAha1-FLAG, Y223F, or Y223E mutants. The cells
were analyzed by immunofluorescence micro-
scopy.
(B) Cytoplasmic and nuclear distribution of hAha1
and Y223F and Y223Emutants in (A) are presented
as average percentage. All the data represent
mean ± SD (**p < 0.005, ***p < 0.0005).
(C) HEK293 cells were transiently transfected with
hAha1-FLAG and Y223F mutant for 24 hr and then
treated with 5 mM MG132 for 6 hr. The hAha1-
FLAG and Y223F mutants were immunoprecipi-
tated (IP) and ubiquitination was assessed by
immunoblotting with anti-ubiquitin antibody. The
IP samples were salt-stripped (0.5 M NaCl) prior to
immunoblotting.
(D) hAha1-FLAG (WT), Y223F, or Y223E mutants
were transiently transfected in HEK293 cells for
24 hr. The cells were then treated with CHX
(100 mg/ml) and harvested at the indicated time
points. The hAha1 was visualized by immuno-
blotting.Finally, the rate of hAha1 protein degradation was determined
by cycloheximide (CHX) chase analysis. The non-phosphorylat-
able hAha1-Y223F mutant was markedly more stable compared
to the wild-type hAha1 (Figure 2D). Conversely, the phosphomi-
metic Y223E mutant was highly unstable supporting a model
where c-Abl mediated phosphorylation of Y223 leads to hAha1
ubiquitination and degradation in the proteasome.
Impact of hAha1 Phospho-Y223 Mutants on hHsp90
Chaperone Activity
Aha1 interacts with a diverse range of proteins (Sun et al., 2015).
To better understand the effect of phosphorylation on the global
interactions of hAha1, we applied a quantitative liquid chroma-
tography-tandem mass spectrometry (LC–MS/MS) proteomics
approach, comparing the interactomes of FLAG-hAha1-Y223E
to FLAG-hAha1-Y223F (Figure S3A; Table S2). The mass spec-
trometry proteomics data have been deposited to the Proteo-Cell Reports 12, 1006–1018,meXchange Consortium via the PRIDE
partner repository with the dataset
identifier PXD001737. We identified 99
candidate partners of hAha1, 84% (83/
99) of which demonstrated preferential
binding to the phosphomimetic isoform
of hAha1 (Figures S3B and S3C; Table
S2). Significant enrichment of several
GeneOntology (GO) termswas observed,
including metabolism, ribosomal com-
ponents, and transcription/translation
(Figure S3B).
Interestingly, binding to major chaper-
ones, including human Hsp70 (hHsp70)and hHsp90 was significantly increased upon hAha1 phosphor-
ylation. hAha1 is known to interact and activate hHsp90 ATPase
activity (Panaretou et al., 2002). Phosphorylation of hHsp90 can
affect its binding to hAha1 (Mollapour et al., 2011; Soroka et al.,
2012; Xu et al., 2012), therefore, we queried whether phosphor-
ylation of hAha1 impacts binding to hHsp90. FLAG-tagged wild-
type hAha1, non-phosphorylatable Y223F, and phosphomimetic
Y223E mutants were transiently expressed in HEK293 cells.
hAha1 proteins were isolated with anti-FLAG M2 affinity gel
and interaction with hHsp90 and co-chaperones was examined
by western blot analysis. In agreement with our proteomic study,
the non-phosphorylatable hAha1-Y223F association with Hsp90
was completely abrogated (Figure 3A). Conversely, the interac-
tion of hAha1-Y223E mutant with hHsp90a was significantly
stronger than the wild-type hAha1 (Figure 3A). In order to directly
demonstrate that the phosphorylation of hAha1 promotes its
interaction with hHsp90, we treated HEK293 cells transientlyAugust 11, 2015 ª2015 The Authors 1009
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Figure 3. Tyrosine Phosphorylation of
hAha1 Is Essential for Binding to Hsp90
(A) HEK293 cells were transiently transfected
with empty plasmid (C), WT hAha1-FLAG (WT),
non-phosphorylatable Y223F, or phosphomimetic
Y223E mutants. The hAha1-FLAG protein was
immunoprecipitated (IP) and co-immuno-
precipitating (co-IP) of hHsp90 (including a and b
isoforms) was examined by immunoblotting.
(B) HEK293 cells transiently expressing hAha1-
FLAG (WT) or the non-phosphorylatable Y223F
mutant were treated with 20 mM DPH for 6 hr prior
to lysis. The hAha1-FLAG proteins were immu-
noprecipitated (IP) and co-immunoprecipitating
(co-IP) hHsp90 was detected by immunoblotting.
(C) The c-Abl+/+ and c-Abl deficient c-Abl/
MEF cells were transiently transfected with
hAha1-FLAG (WT) or the non-phosphorylatable
Y223F mutant. The immunoprecipitation of
hAha1-FLAG proteins and co-immunoprecipitat-
ing (co-IP) of hHsp90 were detected by immuno-
blotting.
(D) Co-immunoprecipitating (co-IP) of PP5 and
Hsp70 in (A) were examined by immunoblotting.
(E) In vitro ATPase activity of hHsp90a-HA isolated
from PC3 cells. The reaction was also performed
in the presence of 10 mM ganetespib. All the data
represent mean ± SD (**p < 0.005).
(F) The ATPase activity was stimulated by hAha1-
FLAG (WT) or the phospho mutants Y223E and
Y223F isolated from HEK293 cells. All the data
represent mean ± SD (**p < 0.005).
(G) Indicated hAha1-FLAG constructs were
transfected in HEK293 cells. The hAha1 was
immunoprecipitated (IP) with anti-FLAG agarose;
co-immunoprecipitating (co-IP) c-Abl and phos-
pho-Tyr89, Raf-1, c-Src, Wee1, Ulk1, and Cdk4
proteins were detected by immunoblotting.
(H) HEK293 cells were co-transfected with CFTR
and hAha1-FLAG (WT) and Y223F and Y223E
mutants. After 24 hr, CFTR, hAha1-FLAG, and
hHsp90 were detected by immunobloting.
(I) HEK293 cells transiently transfected with
hAha1-FLAG,Y223F, andY223E for 24 hr and then
treated with 10 mM dexamethasone for 1 hr (time
0). The cells were then washed and incubated in
dexamethasone free media. The GR activity was
monitored by western blot analysis using anti-
phospho-Ser211-GR and total GR antibodies.expressing wild-type hAha1-FLAG or Y223F mutant with 20 mM
DPH and then isolated these proteins by anti-FLAG M2 affinity
gel. The hHsp90 was co-immunoprecipitated with hAha1-
FLAG, and this interaction was enhanced in DPH treated cells
(Figure 3B). However, we did observe hAha1-Y223F association
with hHsp90 even in DPH treated cells (Figure 3B). Similar results
were also obtained from c-Abl/ MEF cells (Figure 3C), there-
fore providing convincing evidence that c-Abl mediated phos-
phorylation of hAha1 promotes its interaction with hHsp90. We
further validated our proteomic data by observing hHsp70 inter-
action with the phosphomimetic hAha1 mutant Y223E, presum-
ablymediated by hHsp90 (Figure 3D).We have previously shown
that the PP5 co-chaperone is also found in complexes contain-
ing hAha1 and Hsp90 (Xu et al., 2012). The phosphomimetic1010 Cell Reports 12, 1006–1018, August 11, 2015 ª2015 The AuthohAha1-Y223E mutant moderately enhanced the amount of PP5
found in these complexes, in comparison to the amount of PP5
that was co-immunprecipitated with the wild-type hAha1 (Fig-
ure 3D). In contrast, PP5 is absent in complexes that contain
the hAha1-Y223Fmutant (Figure 3D). It is noteworthy that neither
the wild-type hAha1 nor the phospho mutants were able to form
a complex with the other co-chaperones (HOP, p23, CHIP, and
Cdc37), (Figure S3C).
ATPase activity of hHsp90 is essential for its chaperone func-
tion and hAha1 is a potent stimulator of this activity (Panaretou
et al., 2002). We transiently expressed hHsp90a-HA in the pros-
tate cancer PC3 cell line, wild-type hAha1-FLAG, and the Y223
phosphomutants in HEK293 cells. Proteinswere immunoprecip-
itated, salt stripped, and competed off the HA or FLAG affinityrs
beads with the relevant peptides (Figure S4A). The quality of the
isolated proteins was examined by Coomassie staining of the
SDS-PAGE (Figure S4B). These purified proteins were quantified
and used at a ratio of 1:2, hHsp90a:hAha1 in the PiPer Phos-
phate Assay Kit (Thermo Fisher Scientific), (Experimental Proce-
dures) in the presence of ATP as substrate as previously
described (Kamal et al., 2003). Wemeasured the ATPase activity
of isolated hHsp90a in vitro as previously described (Kamal et al.,
2003) (Figures 3E, S4C, and S4D). Addition of 10 mM ganetespib
inhibited ATPase activity (Figures 3E and S4D).
Addition of wild-type hAha1, comprised of phospho- and
non-phosphorylated Y223, stimulated ATPase activity of the
hHsp90a 5-fold higher than that of hHsp90a, alone, while
hAha1-Y223F caused minimal increase in ATPase activity (1.5-
fold increase) (Figures 3F and S4E). In contrast, the phosphomi-
metic hAha1-Y223E mutant stimulated hHsp90a ATPase by 8.5-
fold (Figures 3F and S4E). ATP turnover was expressed as mmol
Pi per mol per minute for hHsp90a alone and in the presence of
hAha1 (wild-type and Y223 mutants), (0.84 = hHsp90a), (4.22 =
hHsp90a + wild-type hAha1), (1.26 = hHsp90a + hAha1-
Y223F), and (7.15 = hHsp90a and hAha1-Y223E), (Figure S4E).
These data are comparable to previously reported ATPase turn-
over rates of hHsp90a (Kamal et al., 2003). Also, overexpression
of wild-type hAha1 or the phospho mutants did not affect the
Hsp90 binding to ATP-agarose (Figure S4F). It is noteworthy
that isolated hAha1 and the mutant proteins had no contami-
nating ATPase activity (Figure S4D).
We previously demonstrated that hAha1 co-exists in an
hHsp90-kinase client complex (Xu et al., 2012). Therefore, we as-
sessed the impact of Y223F and Y223E mutations on hAha1
interaction with kinase clients. We transiently expressed FLAG-
tagged wild-type hAha1 and the Y223 phospho mutants in
HEK293 cells. Following immunoprecipitation with anti-FLAG
M2 affinity gel, we observed hAha1 in complex with the endog-
enous active (phospho-S89) c-Abl, Raf-1, c-Src, Wee1, and
Ulk1 kinases, but not Cdk4 (Figure 3G). These kinases formed
a stronger interaction with the phosphomimetic Y223E mutant
than did the wild-type hAha1 (Figure 3G). Conversely, associa-
tion of the non-phosphorylatable Y223F mutant with c-Abl,
Raf-1, c-Src, Wee1, and Ulk1 was completely abolished (Fig-
ure 3G). Overexpression of hAha1 compromises the folding of
CFTR (Koulov et al., 2010; Wang et al., 2006). To examine the ef-
fects of Y223 phospho mutants on Hsp90 chaperone function,
we assessed their impact on steady-state expression of CFTR
protein in mammalian cells. HEK293 cells were transiently
co-transfected with CFTR and FLAG-hAha1, or Y223F or
Y223Emutants. Empty plasmid pcDNA3 (C) was used as a nega-
tive control. Western blot analysis of these samples using anti-
CFTR antibody detected a doublet (Figure 3H), with the upper
band representing the mature Golgi-processed glycoform of
CFTR found at the cell surface and the lower band an immature
core-glycosylated protein (Figure 3H). Overexpression of the
non-phosphorylatable Y223F mutant did not reduce the stability
of CFTR (Figure 3H), confirming its inability to bind and activate
hHsp90. In contrast, overexpression of the phosphomimetic
hAha1-Y223E mutant displayed a significant reduction of
CFTR protein (Figure 3H). The enhanced interaction of Y223E-
hAha1 mutant with hHsp90 increases chaperone activity and,Celltherefore, reduces the expression of CFTR. Finally, we tran-
siently expressed hAha1-FLAG and Y223 phosphomutants in
HEK293 cells and then stimulated the cells with 10 mM dexa-
methasone for 1 hr, representing time 0. Cells were then washed
and incubated in dexamethasone free media. GR activity was
monitored by western blot analysis using anti-phospho-
Ser211-GR antibody. Overexpression of the non-phospho-
hAha1-Y223F mutant maintained the GR activity even 16 hr
post dexamethasone treatment (Figure 3I). However, overex-
pression of the phosphomimetic hAha1-Y223E caused a rapid
reduction in GR activity (Figure 3I).
These data confirm the hypothesis that phosphorylation of
hAha1-Y223 increases binding to Hsp90 and compromises the
chaperoningand theactivityof theclients thatare ‘‘difficult’’ to fold.
Phosphorylation of hAha1-Y223 Affects Chaperoning
of the Clients
The budding yeast S. cerevisiae was used to further investigate
the impact of hAha1 Y223 phosphorylation on Hsp90 chaperone
function. Aha1 is an evolutionarily conserved co-chaperone, and
it has been previously shown that deletion of yAHA1 renders
cells temperature-sensitive on glucose (YPED) and respiratory
growth media (YPEG) (Panaretou et al., 1998). Since we did
not observe tyrosine phosphorylation of hAha1 in yeast (data
not shown), we hypothesized that yAha1 acts through a different
mechanism to initiate its interaction with yHsp90. Therefore, the
same effect should be displayed when either hAha1 or the non-
phosphorylatable hAha1-Y223F mutant is expressed in yeast.
This turned out to be the case, as overexpression of hAHA1
and the Y223F mutant, under control of the yAHA1 native pro-
moter on a centromeric (single copy) plasmid, reverted the tem-
perature sensitivity phenotype of the yaha1 knockout cells on
both YPED and YPEG media (Figure 4A). Furthermore, both
forms of hAha1 bound to yHsp90 similarly to wild-type yAha1
(Figure 4B). Expression of the phosphomimetic Y223E mutant
did not revert the temperature-sensitivity of yaha1D cells on
YPEG (Figure 4A) and, compared to the wild-type yAha1, its as-
sociation to yHsp90 was enhanced (Figure 4B). These data indi-
cate that expression of Y223E in yeast has a dominant-negative
effect on initiating its binding with Hsp90. These results are also
concordant with our observations in mammalian cells.
We employed these yeast strains to examine the effects of the
Y223E mutant on chaperoning of kinase and non-kinase clients.
The tyrosine kinase, v-Src, is an established Hsp90 client, and its
expression in yeast causes cell death (Nathan and Lindquist,
1995). v-Src expression and upregulation of protein tyrosine
phosphorylation as the result of v-Src activity was significantly
reduced in the yaha1D yeast (Figure 4C), implying compromised
Hsp90 chaperone function. Expression of yAHA1, hAHA1, or the
non-phosphorylatable Y223F mutant restored the defect in
yHsp90 function. In contrast, v-Src expression and tyrosine
phosphorylation of the protein lysate was undetectable in the
hAha1-Y223E mutant (Figure 4C).
GR is another well-characterized Hsp90 non-kinase client that
provides a sensitive assay for Hsp90 function in yeast (Garabe-
dian and Yamamoto, 1992). To assess the impact of Y223 muta-
tion on GR activity, we transformed the above yeast cells with a
GR expression plasmid also carrying a glucocorticoid-regulatedReports 12, 1006–1018, August 11, 2015 ª2015 The Authors 1011
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Figure 4. Phosphorylation of hAha1-Y233
Impacts the Chaperoning of Hsp90 Clients
(A) yAha1 deleted cells (yaha1D) expressing
empty-plasmid pRS314 (C), yAha1, hAha1,
hAha1-Y223F, or hAha1-Y223E mutants were
grown on YPEG (respiratory) liquid media at 28C
for 24 hr and 1:10 dilution series were spotted on
YPEG agar. Plates were incubated at either 30C
or 40C for 5 days.
(B) Yeast cells in (A) expressing indicated Aha1-
FLAG under yAHA1 native promoter were used to
immunoprecipitate (IP) Aha1 with anti-FLAG
agarose. The co-immunoprecipitation (co-IP) of
yHsp90 was analyzed by immunoblotting.
(C) Indicated yeast cells containing v-SRC under
GAL1 promoter were grown on raffinose () or
galactose (+) media. v-Src and total phosphotyr-
osine were analyzed by immunoblotting.
(D) GR-lacZ activity was assessed in the indicated
yeast strains. The data are expressed as a per-
centage of the activity observed in WT cells. The
mean ± SD from values obtained in three inde-
pendent experiments with **p < 0.005 are pre-
sented. The levels of yAha1, hAha1-FLAG,
yHsp90, and GR were analyzed by immunoblot-
ting.
(E) Yeast strains in (A) with HSE-lacZ were heat
shocked (40 min at 39C). The heat shock
response activity was measured in three inde-
pendent experiments. The hAha1-FLAG and
yHsp90 protein levels were assessed by immu-
noblotting. All the data represent mean ± SD (**p <
0.005).LacZ reporter gene. Deletion of yAHA1 increased the GR activity
by 66% (Figure 4D). Expression of yeast, hAha1, or Y223F
mutant reduced the GR activity to the same levels as in the
wild-type cell (Figure 4D). Yeast cells expressing the phosphomi-
metic Y223E mutant had only 18% GR activity relative to wild-
type cells (Figure 4D).
We also tested the effect of hAha1 phosphorylation on HSF1
transcriptional activity. Previous work showed that Hsf1 is an
Hsp90 client, and their interaction suppresses Hsf1 activity
(Hjorth-Sørensen et al., 2001). Compromised Hsp90 chaperone
function leads to induction of Hsf1 activity in yeast even in the
absence of heat shock (Hjorth-Sørensen et al., 2001). Although
deletion of yAHA1 in yeast did not affect the heat shock
response, expression of the phosphomimetic Y223E mutant
led to a 2.5-fold increase in the heat shock response upon
heat shock stress compared to the wild-type hAha1 cells (Fig-
ure 4E). Taken together, these data suggest that expression of
the Y223E affects the chaperoning of kinase and non-kinase cli-
ents such as v-Src, GR, and Hsf1.
Pharmacological Inhibition of c-Abl Sensitizes Cancer
Cells to Hsp90 Inhibitors
Previous work has shown that knock down of hAHA1 could
sensitize cancer cells to Hsp90 inhibitors (Holmes et al., 2008).
Lack of phosphorylation of Y223 prevents hAha1 from binding1012 Cell Reports 12, 1006–1018, August 11, 2015 ª2015 The Authoto hHsp90 (Figure 3A), and this should phenocopy the effect of
hAha1 knockdown. It follows that any strategy that limits
hAha1 association with hHsp90 should have the same effect
as depletion of hAha1, namely sensitization of cells to Hsp90 in-
hibitors. Accordingly, given that c-Abl phosphorylates Y223, we
hypothesized that absence or pharmacological inhibition of
c-Abl would sensitize cancer cells to Hsp90 inhibitors. We first
explored c-Abl/ and c-Abl+/+ MEF cell lines using the bio-
tinylated Hsp90 inhibitor, ganetespib, and streptavidin beads
to affinity purify hHsp90 protein from cell lysates. We observed
that lack of c-Abl enhances ganetespib recognition of wild-
type hHsp90 (both a and b isoforms) (Figures 5A and 5B). The
impact of phosphorylation of Y223-hAha1 on hHsp90 binding
to ganetespib was further tested by transiently expressing
hAha1 phospho-Y223F and Y223E mutants in c-Abl/ MEF
cells. Expression of the non-phospho Y223F mutant did not
impact the Hsp90 binding to ganetespib, however, expression
of hAha1-Y223E markedly reduced the Hsp90 affinity to gane-
tespib in c-Abl/ MEF cells (Figures 5A and 5B). We further
confirmed these data by showing c-Abl/ MEF cells to be
more sensitive to ganetespib, as evident by elevated levels of
apoptotic markers at lower drug concentrations (Figure 5C).
Although we cannot absolutely rule out the possibility that
absence of c-Abl may indirectly sensitize the cells to Hsp90
inhibitors, the fact that overexpression of hAha1-Y223E inrs
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Figure 5. c-Abl Inhibition Hypersensitizes
Prostate Cancer and RCC Cell Lines to
Hsp90 Inhibitors
(A) Lysates fromWT (c-Abl+/+) and c-Abl deficient
(c-Abl/) MEF cell lines also carrying indicated
hAha1 phospho mutant plasmids were incubated
with indicated amounts of biotinylated ganetespib,
followed by streptavidin agarose beads. The
hHsp90a/b was detected by immunoblotting with
anti-hHsp90 monoclonal antibody (16F1).
(B) Total lysate from samples in (A) were tested for
hHsp90 by immunoblotting with anti-hHsp90
(16F1) and anti-FLAG antibodies.
(C) WT (c-Abl+/+) and c-Abl deficient (c-Abl/)
MEF cell lines were treatedwith indicated amounts
of ganetespib for 6 hr. The cleaved PARP and
cleaved caspase-3 were detected by immuno-
blotting.ThehHsp90wasusedasa loadingcontrol.
(D and E) Prostate cancer PC3 cells were treated
with 5 mM c-Abl inhibitor GNF-5 for 24 hr. The cells
were then treated with indicated concentrations of
Hsp90 inhibitors SNX2112 and (E) ganetespib for
an additional 24 hr. Apoptosis was detected by
FACS analysis. The errors bars in (D) and (E)
represent theSDof three independent experiments
(**p < 0.005).
(F) PC3 cells were treated with 5 mM c-Abl inhibitor
GNF-5 for 24 hr and then with indicated concen-
trations of SNX2112 and ganetespib for an addi-
tional 24 hr. Hsp90, c-Abl, active c-Abl (phospho-
Y245), and apoptosis indicator cleaved caspase-3
and cleaved PARP were detected by immuno-
blotting.
(G) RCC Caki-1 and 786-O cell lines were treated
with 5 mM c-Abl inhibitor GNF-5 for 24 hr and then
with indicated concentrations of SNX2112 and
ganetespib for an additional 24 hr. Hsp90, c-Abl,
active c-Abl (phospho-Y245), and apoptosis in-
dicators cleaved caspase-3 and cleaved PARP
were detected by immunoblotting.c-Abl/ MEF cells reversed the drug sensitivity, reduces the
likelihood of this hypothesis.
We next testedwhether pharmacologic inhibition of c-Abl sen-
sitizes cancer cells to Hsp90 inhibitors. The prostate cancer PC3
cell line was treated with different amounts of GNF-5 (a selective
allosteric c–Abl inhibitor) for 24 hr (Zhang et al., 2010). We found
that 5 mMGNF-5 is sufficient to inhibit c-Abl activity (assessed by
level of Y-245 phosphorylation), (data not shown). We subse-
quently treated PC3 cells with 5.0 mM GNF-5 for 24 hr followed
by 0–80 nM SNX2112, ganetespib, or PU-H71 (Hsp90 inhibitors)
for an additional 24 hr (in the continued presence of GNF-5). As a
control, we also treated PC3 cells with Hsp90 inhibitors, alone,
for 24 hr. At the end of the incubation we quantified the percent-
age of apoptotic cells by flow cytometry (by measuring the in-
crease of sub-G1 cellular DNA content Figures 5D, 5E, and
S5). Compared to either GNF-5 or Hsp90 inhibitors alone, com-Cell Reports 12, 1006–1018,bined administration of both drugs had a
synergistic effect on apoptosis (Figures
5D and 5E). These data were confirmed
by assessing the abundance of cleavedcaspase-3 and cleaved PARP, two cellular markers of apoptosis.
Treatment as above with the combination of c-Abl inhibitor,
GNF-5, (5 mM) and Hsp90 inhibitors (SNX2112 and ganetespib)
significantly increased the level of apoptotic markers in PC3
cells, while similar incubation with the individual drugs was inef-
fective (Figure 5F).
Finally, we used two cell lines derived from human clear cell
renal cell carcinoma (ccRCC), Caki-1 and 786-O. These cells
were pretreated with 5 mM GNF-5 for 24 hr prior to addition of
40 and 80 nM ganetespib (Figure 5G). Pharmacologic inhibition
of c-Abl also sensitizes these two ccRCCcell lines to ganetespib.
Ex Vivo Inhibition of c-Abl Hypersensitizes Human RCC
Tumors to Hsp90 Inhibitor Ganetespib
ATP competitive inhibitors of Hsp90 such as ganetespib have
the remarkable ability to accumulate in tumors, but not in normalAugust 11, 2015 ª2015 The Authors 1013
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Figure 6. Pharmacologic Inhibition of c-Abl Increases Accumulation of Ganetespib in Human RCC Tumors from Patients
(A) Human RCC tumors from patients were stained with hematoxylin and eosin (H&E). Patients 1 and 2 (P1 and P2) diagnosed with clear cell, Patient 3 (P3) with
papillary type II, and Patient 4 (tumors 4a, 4b, and 4c) with papillary type I RCC are shown. The scale bar represents 20 mm.
(B) Within 15 min of removal of tumors in (A) by radical nephrectomy, they were dissected into 3 mm3 pieces that were cultured in medium
containing 5 mM GNF-5 for 24 hr and then with 0.5 mM BODIPY FL-ganetespib (STA-12-9455) for an additional 6 hr. There were 107 cells that were
isolated from the tumors and the efficacy of c-Abl inhibition was confirmed by immunoblotting of the lysates with anti-phospho Y89-c-Abl monoclonal
antibody.
(legend continued on next page)
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Figure 7. c-Abl Mediated Phosphorylation
of the Co-chaperone hAha1-Y223 and Its
Binding to Hsp90
c-Abl tyrosine kinase transiently binds and phos-
phorylates hAha1-Y223 (1). This, in turn, promotes
its binding to Hsp90 and formation of hAha1-
Hsp90-c-Abl complex (2).tissues (Chan et al., 2008). Here, we used tumors from patients
with RCC and observed whether inhibition of c-Abl increased
their uptake of ganetespib. Based on histopathology, RCCs
can be classified into several types. We used tumors from pa-
tients with ccRCC, papillary type I, and type II RCC (Figure 6A).
Within 15 min of removal of tumors by radical nephrectomy, hu-
man RCC tumors were dissected into 3 mm3 pieces that were
cultured in medium containing 5 mM GNF-5 for 24 hr and then
with 0.5 mMboron-dipyrromethene (BODIPY) fluorophore-conju-
gated ganetespib (STA-12-9455), (FL-ganetespib) for an addi-
tional 6 hr.
Using an ex vivo approach, approximately 107 cells were then
isolated from these RCC solid tumors (Kedar et al., 1982). West-
ern blot analysis showed that GNF-5 indeed inactivated c-Abl,
and there also were relatively equal amounts of hAha1 and
hHsp90 in these samples (Figure 6B). We next stained live cells
with propidium iodide (PI) prior to fixation and analysis by flow
cytometry. Our data show that RCC tumor cells were able to
take up FL-ganetespib (Figure 6C). However, inhibition of c-Abl
significantly increases the uptake of FL-ganetespib in these cells
(Figures 6C–6E).
DISCUSSION
Co-chaperones are regulatory components of Hsp90, howev-
er, the underlying mechanisms of their regulation by PTMs
are poorly understood. In this study, we show that hAha1
co-chaperone is phosphorylated on tyrosine residues. c-Abl
was identified as the kinase that targets a conserved tyro-
sine-223 on hAha1 both in vitro and in vivo. This, in turn, pro-
motes hAha1 interaction with hHsp90a. Mutation of Y223 to
non-phosphorylatable phenylalanine (Y223F) disrupts hAha1
binding to hHsp90a and, subsequently, did not alter its
ATPase activity. The phosphomimetic hAha1-Y223E mutant
bound stronger to hHsp90a than the wild-type hAha1 and(C) Cells from (B) were stained with PI, fixed, and analyzed by flow cytometry.
(D) Percentage (%) geometric mean fluorescence intensity (MFI) of the RCC cells from (B) treated with GNF
(E) Geometricmean fluorescence intensity (MFI) data from (C) were transformed to log10 values prior to statistic
plot with the mean and the error bars representing the SE of the mean (*p < 0.05) is shown.
Cell Reports 12, 1006–1018,stimulated the hHsp90a ATPase activity
by almost 8.5-fold relative to wild-type
hAha1.
Our previouswork showed that bacteri-
ally expressed and purified hAha1 and
hHsp90a, lacking any PTMs, interact
and form a complex with each other,
in vitro, and hAha1 also stimulateshHsp90aATPase activity (Xu et al., 2012). PTMs of hHsp90, how-
ever, play a major role in its binding to the co-chaperones
including hAha1 (Mollapour et al., 2011, 2014; Xu et al., 2012).
Work by Buchner and co-workers has shown that yAha1 binding
to yHsp90 is comprised of two steps. yAha1 N-domain (amino
acids 1–156) makes initial contact with a motif in the yHsp90
middle-domain and this positions the yAha1 C-domain (amino
acids 157–356) to interact with the yHsp90 N-domains (Li et al.,
2013; Retzlaff et al., 2010). Tyrosine 223 is located in the
C-domain of hAha1; thus, our data suggest that failure to estab-
lish contact with the hHsp90 N-domain significantly weakens
overall stability of the complex, as previously suggested by Kou-
lov et al. (2010). We therefore propose a regulatory paradigm
where PTMs of Hsp90 (Mollapour et al., 2011, 2014; Xu et al.,
2012) and (at least) tyrosine phosphorylation of hAha1-Y223 pro-
vide the signaling cues for association and complex formation of
these twoproteins (Figure 7).While it cannot be formally excluded
that enhanced interaction of phospho-hAha1 and Hsp90 may
be facilitated by c-Abl kinase itself, we consider this very unlikely
in view of the fact that phosphomimetic hAha1-Y223E mutant
stimulated hHsp90a ATPase in vitro by 8.5-fold.
How does hAha1 tyrosine phosphorylation affect chaper-
oning of the clients? hAha1 plays a major role in chaperoning
of v-Src, GR, and CFTR. Compared to the wild-type hAha1,
the phosphomimetic Y223E mutant binds more strongly to
hHsp90a and thus increases its ATPase activity, which appears
to compromise the chaperoning of CFTR. Interestingly, the
expression of the non-phosphorylatable hAha1-Y223F did not
affect the folding of CFTR, providing further evidence that the
Y223F mutant is unable to bind and stimulate Hsp90 ATPase
activity. We have also shown that the phosphomimetic mutant
Y223E elicited a stronger interaction in the hHsp90 in complex
with kinase clients such as c-Abl, Raf-1, c-Src, Wee1, Ulk1,
and Cdk4, as well as the co-chaperones PP5 and hHsp70.
This could be the result of increased chaperone cycling that-5 and/or FL-ganetespib.
al analysis. For each tumor treatment, a scatter dot
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does not allow kinases and/or co-chaperones to dissociate
from hHsp90. Using a yeast system to express the hAha1-
Y223E in yaha1D mutant, we showed that the chaperoning of
GR, Hsf1, and v-Src were significantly compromised. These ob-
servations may be the result of hyperactive chaperone cycle,
therefore compromising the necessary dwell time between
Hsp90 and the clients.
Phosphorylation of hAha1-Y223 causes ubiquitination and
degradation of hAha1 in the proteasome. This indicates that
the amount of phosphorylated Aha1 is tightly regulated. Addi-
tionally, the phosphomimetic Y223E tends to be retained in the
cytoplasm compared to the wild-type hAha1 and non-phosphor-
ylatable Y223F mutant localized both in the nucleus and cyto-
plasm. These data suggest that Aha1 may have additional
cellular functions that are independent of binding and activating
the Hsp90 ATPase activity. We explored this hypothesis, by per-
forming a quantitative proteomic analysis with the phospho-
hAha1 mutants. We observed hAha1 involvement in different
cellular functions, especially interactions with components of
the small (40S) and large (60S) subunits of the ribosome and
ribosomal proteins such as elongation factors EF3 and EF4
(Figure S3B). This is consistent with previous work on hAha1
interactome (Sun et al., 2015) and also similar to the previously
reported involvement of Hsp90 and co-chaperones Crp6/7 in ri-
bosomal or pre-ribosomal functions (Kim et al., 2006; Schlatter
et al., 2002; Tenge et al., 2014). Interestingly, we found that
POM121 transmembrane nucleoporin dissociated from the
phosphomimetic Y223E mutant (Figure S3B). Therefore, these
data may partly explain the inability of hAha1-Y223E accumula-
tion in the nucleus.
Hsp90 inhibitors are currently employed in clinical trials for
treating cancer patients. Therefore, novel strategies to enhance
their efficacy are actively sought. Previous data from Work-
man’s research group has shown that downregulation of
hAHA1 results in increased tumor sensitivity to the first gener-
ation Hsp90 inhibitor, Tanespimycin (17-N-allylamino-17-de-
methoxygeldanamycin, 17-AAG) (Holmes et al., 2008). The au-
thors also suggested a potential therapeutic strategy to
increase the sensitivity of cancer cells to Hsp90 inhibitors by
disrupting the hHsp90-hAha1 complex. Our data, here, provide
further direct evidence that inhibition of c-Abl hypersensitizes
prostate cancer and RCC cell lines to Hsp90 inhibitors, gane-
tespib and SNX2112. We have also shown that pharmacologic
inhibition of c-Abl increases accumulation of ganetespib in can-
cer cells from patients with ccRCC, papillary type I, and type II
RCC.
Our data also provide an explanation for previous findings on
the synergistic effects of the combination of imatinib (STI571,
Glivec, and Gleevec) plus 17-AAG on chronic myeloid leukemia
(CML) cell lines (Radujkovic et al., 2005). Fusion of bcr-abl
gene is associated with CML, and it has been shown that imati-
nib sensitizes CML cell lines to 17-AAG. Similar results were also
observed with imatinib-resistant CML cell lines (Radujkovic
et al., 2005). Based on our data, we speculate that imatinibmedi-
ated inhibition of Bcr-Abl, and possibly the endogenous c-Abl
reduces the phosphorylation of hAha1-Y223, and therefore dis-
rupts its association with Hsp90. This is turn enhances Hsp90
binding to its inhibitors.1016 Cell Reports 12, 1006–1018, August 11, 2015 ª2015 The AuthoEXPERIMENTAL PROCEDURES
Statistical Analysis
The data presented are the representative or examples of three biological rep-
licates unless it is specified. Data were analyzed with unpaired t test and one-
way ANOVA analysis. Asterisks in figures indicate significant differences (* p <
0.05, ** p < 0.005, and *** p < 0.0005). The error bars represent the SD or SE for
three independent experiments, unless it is indicated.
Plasmids and Growth Media
Plasmids, a list of primers (Table S3), and media conditions for both yeast and
mammalian cells are provided in the Supplemental Information.
Protein Extraction, Co-immunoprecipitation, and Immunoblotting
Total protein extracts were prepared and analyzed by western blotting, as
described previously (Mollapour et al., 2011). Detailed methods for protein
extraction, precipitations, and detection by western blotting are presented in
Supplemental Information.
Assays for Hsp90 Client Activity
v-Src induction and activation were analyzed as described previously (Mol-
lapour et al., 2011). Expressed v-Src protein was detected with EC10
mouse antibody (Millipore) and v-Src activity with 4G10 mouse anti-phos-
photyrosine antibody (Millipore). GR assay was performed as described
previously (Garabedian and Yamamoto, 1992), as was measurement of
HSE-LacZ expression (Hjorth-Sørensen et al., 2001). STE11DN induction
was analyzed as described previously (Flom et al., 2008; Louvion et al.,
1998). Additional details are found in Supplemental Information.
Immunofluorescence Staining and Microscopy
The procedures for immunofluorescence staining and confocal microscopy
were described previously (Bourboulia et al., 2013). Detailed methodology
is found in Supplemental Information.
Flow Cytometry Analysis
PC3cells treatedwithGNF-5, ganetespib, or SNX2112were analyzed for SubG1
usingPI. Uptake of fluorescently fluorescein isothiocyanate (FITC)-labeledgane-
tespib (STA-12-9455) (FL-ganetespib) by RCC cells was monitored by flow
cytometry analysis. Detailed methodology is found in the Supplemental
Information.
hAha1 Comparative Interactome Analysis
Interactomes of hAha1-Y223E-FLAG and hAha1-Y223F-FLAG were analyzed
as described previously (Truman et al., 2012). Briefly, hAha1-Y223E-FLAG or
hAha1-Y223F-FLAG protein complexes were purified from 293T cells, trypsin
digested, isotopically labeled, and subjected to LC-MS/MS. For each Hsp90
interactor, a log2 interaction change (Y223E/Y223F) was calculated after
normalization to the bait protein (hAha1). The mass spectrometry proteomic
data have been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identifier PXD001737. Detailed proteomic
methods are provided in the Supplemental Information.
Hsp90 ATPase Activity In Vivo
ATPase activity of hHsp90a isolated from prostate cancer PC3 cells, and its
activation by hAha1 and phospho-Y223 mutants from HEK293 cells were
measured as previously described (Kamal et al., 2003), with exceptions
detailed in Supplemental Information.
Ex Vivo Culture and Analysis of Human RCC Tumors
Tumor tissues of the patients with conventional RCC were obtained with writ-
ten informed consent from the Department of Urology at SUNY Upstate Med-
ical University. Patients had no history of hereditary VHL disease.
At the time of radical or partial nephrectomy, which was done with <15 min
of renal ischemia, RCC tumors were dissected into 3–5 mm3 pieces and
cultured in a presoaked gelatin sponge (Johnson and Johnson) in 24-well
plates containing 2 ml RPMI-1640 with 10% FBS, antibiotic/antimycoticrs
solution, with or without 5 mM GNF-5. Tissues were cultured at 37C for 24 hr
followed by addition of 100 nM fluorescently labeled ganetespib (STA-12-
9455), (FL-ganetespib) and further incubation at 37C for 6 hr.
Using an ex vivo method as previously described (Kedar et al., 1982),
approximately 107 cells were isolated from the RCC solid tumors analysis by
flow cytometry and western blot. All ex vivo experiments with the patients’
samples were performed according to a protocol approved by the SUNY Up-
state Medical University IRB.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.07.004.
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